Brief: Springworks Therapeutics Completes Submission Of New Drug Application To The FDA For Mirdametinib
01/07/2024 11:41
July 1 (Reuters) - SpringWorks Therapeutics Inc
SWTX.O :
* SPRINGWORKS THERAPEUTICS COMPLETES SUBMISSION OF NEW DRUG
APPLICATION TO THE FDA FOR MIRDAMETINIB FOR THE TREATMENT OF
CHILDREN AND ADULTS WITH NF1-PN
* IN H2 2024, PLANS TO FILE MARKETING AUTHORIZATION
APPLICATION
WITH EMA FOR MIRDAMETINIB
Source text for Eikon: ID:nGNX915mYC
Further company coverage: SWTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SpringWorks Therapeutics
See all newsBrief: Merck KGaA Completes Acquisition Of Springworks Therapeutics
Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN